ScoreWhy is Marksans Pharma Ltd ?
1
High Management Efficiency with a high ROE of 16.65%
2
Company has a low Debt to Equity ratio (avg) at 0 times
3
Poor long term growth as Operating profit has grown by an annual rate 10.10% of over the last 5 years
4
Flat results in Dec 25
- ROCE(HY) Lowest at 16.13%
- INVENTORY TURNOVER RATIO(HY) Lowest at 2.86 times
5
Stock is technically in a Bullish range
- The technical trend has deteriorated from Bullish on 22-May-26 and has generated 4.05% returns since then
- Multiple factors for the stock are Bullish like MACD, Bollinger Band and KST
6
With ROE of 13.1, it has a Expensive valuation with a 3.6 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -10.19%, its profits have fallen by -2.2%
7
High Institutional Holdings at 23.34%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 9.3% over the previous quarter.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Marksans Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Marksans Pharma for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Marksans Pharma
82.52%
-0.27
38.19%
Sensex
-11.8%
-0.49
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
17.87%
EBIT Growth (5y)
14.58%
EBIT to Interest (avg)
28.58
Debt to EBITDA (avg)
0.40
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
1.05
Tax Ratio
24.51%
Dividend Payout Ratio
9.53%
Pledged Shares
0
Institutional Holding
23.66%
ROCE (avg)
26.15%
ROE (avg)
15.04%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
27
Industry P/E
36
Price to Book Value
4.62
EV to EBIT
21.73
EV to EBITDA
18.68
EV to Capital Employed
5.61
EV to Sales
4.20
PEG Ratio
0.57
Dividend Yield
0.29%
ROCE (Latest)
21.13%
ROE (Latest)
13.82%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
NET SALES(Latest six months)
At Rs 1,696.91 cr has Grown at 27.74%
PBDIT(Q)
Highest at Rs 213.03 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 25.34%
PBT LESS OI(Q)
Highest at Rs 181.17 cr.
PAT(Q)
Highest at Rs 157.17 cr.
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 989.65 cr
EPS(Q)
Highest at Rs 3.47
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Marksans Pharma
Operating Profit (PBDIT) - Quarterly
Highest at Rs 213.03 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 25.34% and Grown
each quarter in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 181.17 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 181.17 cr has Grown at 51.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 119.51 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 157.17 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 157.17 cr has Grown at 50.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 104.48 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Latest six months
At Rs 1,696.91 cr has Grown at 27.74%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 3.47
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 989.65 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
